clinical trial · NCT02550652
A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)
Hoffmann-La Roche·phase2·completed·n = 126
Lupus NephritisMycophenolate Mofetil/Mycophenolic AcidObinutuzumabPlaceboMethylprednisolonePrednisone
brief summary
This Phase II study will compare the efficacy and safety of obinutuzumab plus mycophenolate mofetil (MMF)/mycophenolic acid (MPA) with placebo plus MMF/MPA in participants with proliferative LN.
started
Nov 13, 2015
primary completion
Jan 15, 2019
completion
Aug 2, 2023
last updated
Aug 27, 2024
official title
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol